AR095070A1 - Compuesto híbrido con una porción antibiótica y una porción esteroide, uso de dicho compuesto para preparar una composición farmacéutica tópica oftálmica y dicha composición farmacéutica - Google Patents
Compuesto híbrido con una porción antibiótica y una porción esteroide, uso de dicho compuesto para preparar una composición farmacéutica tópica oftálmica y dicha composición farmacéuticaInfo
- Publication number
- AR095070A1 AR095070A1 ARP140100771A ARP140100771A AR095070A1 AR 095070 A1 AR095070 A1 AR 095070A1 AR P140100771 A ARP140100771 A AR P140100771A AR P140100771 A ARP140100771 A AR P140100771A AR 095070 A1 AR095070 A1 AR 095070A1
- Authority
- AR
- Argentina
- Prior art keywords
- cefimadin
- pharmaceutical composition
- antibiotic
- steroid
- blepharitis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/552—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being an antibiotic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Botany (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un compuesto híbrido que comprende una porción antibiótica y una porción esteroide, o una sal farmacéutica de la misma, que se conectan vía dos enlaces covalentes separados con un enlazador de manera que dichos enlaces covalentes se degradan en vivo para producir los respectivos antibiótico y esteroide independientemente. La porción. antibiótica, es seleccionada entre el grupo formado por levofloxacina, moxifloxacina, gatifloxacina, clindamicina, besifloxacina, gemifloxacina, trovafloxacina, ofloxacina, ciprofloxacina, esparfloxacina, grepafloxacina, norfoxacina, enoxacina, lomefloxacina, fleroxacina, tosufloxacina, prulifloxacina, pazufloxacina, clinafloxacina, garenoxacina, sitafloxacina, loracarbef, cefalexina, cefuroxima, ceftriaxona, ceftaxima, ceftizoxima, ceftibuten, ceftazidima, cefprozil, cefpodoxima, cefoxitina, cefotetan, cefotaxima, cefoperazona, cefixima, cefepima, cefditoren, cefdinir, cefoperaxona, moxalactam, cefazolina, cefamandol, cefadroxil, cefaclor, cefalotina, cefradina, cefacetril, cefalotina, cloramfenicol, tobramicina, estreptomicina, gentamicina, canamicina, amicacina, netilmicina, penicilina g, ticarcilina, meticilina, fenticilina, cloxacilina, dicloxacilina, nafcilina, oxacilina, eritromicina y azitromicina. La porción esteroide es seleccionada entre dexmetasona, betametasona, acetónido de triamcinolona, prednisolona e hidrocortisona. Uso del compuesto hibrido, en donde cada enlace es un enlace éster o un enlace amida, para preparar una composición farmacéutica de utilidad para administrar a un ojo de un mamífero con una infección bacteriana o una inflamación que afecta dicho ojo. La infección bacteriana es seleccionada entre: conjuntivitis, queratitis, blefaritis, endoftalmitis, dacirocistitis, hordéolo, úlceras cornéales, blefaritis anterior, blefaritis posterior, disfunción de glándula meibomiana, enfermedad de ojo seco, (queratoconjuntivitis sicca) dolor ocular e inflamación post-cirugía ocular, conjuntivitis bacteriana, uveítis anterior, ojo rojo, hiperemia, inflamación post- quirúrgica, condiciones inflamatorias de conjuntiva palpebral y bulbar, cornea, y segmento anterior del globo, tal como conjuntivitis alérgica, rosácea ocular, ojo seco blefaritis, endoftalmitis, disfunción. de glándula.meibomiana, queratitis punteada. superficial, queratitis de herpes zoster, iritis, ciclitis, conjuntivitis infectiva seleccionada, daño corneal por radiación química, o quemadura térmica, penetración de cuerpos extraños, y alergia. Composición farmacéutica que comprende al compuesto hibrido, y en donde dicha composición está formulada para administración oftálmica tópica.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361775121P | 2013-03-08 | 2013-03-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR095070A1 true AR095070A1 (es) | 2015-09-16 |
Family
ID=50382688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140100771A AR095070A1 (es) | 2013-03-08 | 2014-03-07 | Compuesto híbrido con una porción antibiótica y una porción esteroide, uso de dicho compuesto para preparar una composición farmacéutica tópica oftálmica y dicha composición farmacéutica |
Country Status (16)
Country | Link |
---|---|
US (1) | US20140256660A1 (es) |
EP (1) | EP2964267A1 (es) |
JP (1) | JP2016510753A (es) |
KR (1) | KR20150128856A (es) |
CN (1) | CN105025930A (es) |
AR (1) | AR095070A1 (es) |
AU (1) | AU2014225682A1 (es) |
BR (1) | BR112015021834A2 (es) |
CA (1) | CA2903438A1 (es) |
IL (1) | IL241076A0 (es) |
MX (1) | MX2015011847A (es) |
RU (1) | RU2015138893A (es) |
SG (1) | SG11201507250YA (es) |
TW (1) | TW201444559A (es) |
WO (1) | WO2014138375A1 (es) |
ZA (1) | ZA201506495B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014138403A1 (en) | 2013-03-08 | 2014-09-12 | Allergan, Inc. | Antibiotic conjugates |
MX2015011948A (es) | 2013-03-08 | 2015-12-09 | Allergan Inc | Antibioticos conjugados directamente relacionados con farmacos esteroides. |
US10272158B2 (en) | 2014-07-03 | 2019-04-30 | Board Of Regents, The University Of Texas System | Compounds for treating biofilm infection |
CN105001296B (zh) * | 2015-07-14 | 2016-11-30 | 中国人民解放军第三军医大学 | 一种一氧化氮供体型地塞米松及制备方法与用途 |
EP3394080B1 (en) | 2015-12-23 | 2023-06-07 | The University Of British Columbia | Lipid-linked prodrugs |
SG11202109152UA (en) * | 2019-06-03 | 2021-12-30 | Aihol Corp | Hyaluronan conjugates and uses thereof |
WO2022232602A1 (en) * | 2021-04-29 | 2022-11-03 | Aerie Pharmaceuticals, Inc. | Stable isoquinoline-corticosteroid conjugates and uses thereof |
WO2023079362A1 (en) * | 2021-11-03 | 2023-05-11 | Ripple Therapeutics Corporation | Processable compositions and use for the same |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010049366A1 (en) * | 2000-02-09 | 2001-12-06 | Alcon Universal Ltd. | Topical solution formulations containing an antibiotic and a corticosteroid |
HRP20030324A2 (en) * | 2003-04-24 | 2005-02-28 | Pliva-Istra�iva�ki institut d.o.o. | Compounds of antiinflammatory effect |
EP1633403A2 (en) * | 2003-05-21 | 2006-03-15 | Control Delivery Systems, Inc. | Codrugs of diclofenac |
US20080138350A1 (en) * | 2006-10-20 | 2008-06-12 | Bennett Michael D | Process for use of fluoroquinolones to reduce or modulate inflammation due to eye disease or ophthalmic surgery |
US20090162858A1 (en) * | 2007-09-18 | 2009-06-25 | Cornish Virginia W | Orthogonal chemical inducer of dimerization |
MX2008014515A (es) * | 2008-09-09 | 2010-04-29 | Allergan Inc | Suspension oftalmica para uso ocular. |
-
2014
- 2014-03-06 MX MX2015011847A patent/MX2015011847A/es unknown
- 2014-03-06 SG SG11201507250YA patent/SG11201507250YA/en unknown
- 2014-03-06 KR KR1020157027831A patent/KR20150128856A/ko not_active Application Discontinuation
- 2014-03-06 RU RU2015138893A patent/RU2015138893A/ru unknown
- 2014-03-06 CA CA2903438A patent/CA2903438A1/en not_active Abandoned
- 2014-03-06 BR BR112015021834A patent/BR112015021834A2/pt not_active IP Right Cessation
- 2014-03-06 JP JP2015561648A patent/JP2016510753A/ja active Pending
- 2014-03-06 EP EP14712948.0A patent/EP2964267A1/en not_active Withdrawn
- 2014-03-06 CN CN201480012847.XA patent/CN105025930A/zh active Pending
- 2014-03-06 US US14/199,101 patent/US20140256660A1/en not_active Abandoned
- 2014-03-06 AU AU2014225682A patent/AU2014225682A1/en not_active Abandoned
- 2014-03-06 WO PCT/US2014/021151 patent/WO2014138375A1/en active Application Filing
- 2014-03-07 AR ARP140100771A patent/AR095070A1/es unknown
- 2014-03-10 TW TW103108200A patent/TW201444559A/zh unknown
-
2015
- 2015-09-02 IL IL241076A patent/IL241076A0/en unknown
- 2015-09-03 ZA ZA2015/06495A patent/ZA201506495B/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW201444559A (zh) | 2014-12-01 |
RU2015138893A (ru) | 2017-04-13 |
US20140256660A1 (en) | 2014-09-11 |
BR112015021834A2 (pt) | 2017-07-18 |
CN105025930A (zh) | 2015-11-04 |
CA2903438A1 (en) | 2014-09-12 |
AU2014225682A1 (en) | 2015-09-24 |
ZA201506495B (en) | 2017-08-30 |
JP2016510753A (ja) | 2016-04-11 |
EP2964267A1 (en) | 2016-01-13 |
WO2014138375A1 (en) | 2014-09-12 |
MX2015011847A (es) | 2016-01-08 |
KR20150128856A (ko) | 2015-11-18 |
SG11201507250YA (en) | 2015-10-29 |
IL241076A0 (en) | 2015-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR095070A1 (es) | Compuesto híbrido con una porción antibiótica y una porción esteroide, uso de dicho compuesto para preparar una composición farmacéutica tópica oftálmica y dicha composición farmacéutica | |
DOP2022000278A (es) | Inhibidores de cisteína proteasas y sus métodos de uso | |
AR095073A1 (es) | Compuesto híbrido con una porción ciclosporina a y una porción de esteroide, uso de dicho compuesto para preparar una composición farmacéutica tópica y dicha composición | |
WO2020150417A2 (en) | Compounds and compositions for treating conditions associated with sting activity | |
EP3817820A1 (en) | Compounds and compositions for treating conditions associated with sting activity | |
PE20181016A1 (es) | Compuestos antivirales de fosfodiamida de ester de beta aminoacido | |
AR054186A1 (es) | Derivados de tetrahidroindazolona y tetrahidroindolona | |
JP2014527407A5 (es) | ||
AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
WO2021067801A1 (en) | Compounds and compositions for treating conditions associated with sting activity | |
PE20141110A1 (es) | Derivados heterociclicos novedosos para el tratamiento de trastornos neurologicos | |
AR087471A1 (es) | Metodos de tratamiento de enfermedades degenerativas de la retina | |
PE20141685A1 (es) | Novedosas dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de transtornos inflamatorios | |
WO2021067805A1 (en) | Oxalamide heterobycyclic compounds and compositions for treating conditions associated with sting activity | |
RU2014123471A (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ ПРОИЗВОДНЫХ 4-ПРЕГЕНЕН-11β-17-21-ТРИОЛ-3,20-ДИОНА | |
MXPA06002088A (es) | Analogos de rifamicina y usos de los mismos. | |
JP2007516291A (ja) | リファマイシンアナログおよびその使用法 | |
JP2014533275A5 (es) | ||
UY29802A1 (es) | Análogos de la feniletilamina y su uso en el tratamiento del glaucoma | |
BR112016001544A8 (pt) | composições farmacêuticas para a administração intraocular que compreende um agente antibacteriano e um agente anti-inflamatório | |
EA201892153A1 (ru) | Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf | |
AR095071A1 (es) | Compuesto híbrido con una porción antibiótica y una porción esteroide, uso de dicho compuesto para preparar una composición farmacéutica tópica oftálmica y dicha composición | |
EP4182030A1 (en) | Compounds and compositions for treating conditions associated with sting activity | |
EA201992343A1 (ru) | Замещенные бициклические гетероциклические соединения в качестве ингибиторов надфн-оксидазы | |
CO2023004420A2 (es) | Compuestos heterocíclicos como inhibidores del bromodominio cbp/ep300 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |